Conestoga Capital Advisors LLC Has $127.91 Million Position in Repligen Corporation $RGEN

Conestoga Capital Advisors LLC lessened its holdings in Repligen Corporation (NASDAQ:RGEN) by 2.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 956,913 shares of the biotechnology company’s stock after selling 19,994 shares during the period. Repligen comprises approximately 2.0% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 23rd biggest position. Conestoga Capital Advisors LLC owned about 1.70% of Repligen worth $127,911,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Repligen by 3,219.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after acquiring an additional 400,970 shares during the period. Geneva Capital Management LLC lifted its position in shares of Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares in the last quarter. Blue Whale Capital LLP acquired a new stake in shares of Repligen during the second quarter worth approximately $35,782,000. Norges Bank purchased a new position in Repligen during the second quarter valued at approximately $30,991,000. Finally, Schroder Investment Management Group purchased a new position in Repligen during the second quarter valued at approximately $25,672,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anthony Hunt sold 20,000 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the sale, the director owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This trade represents a 19.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 49,657 shares of company stock worth $7,721,077. 1.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RGEN. Evercore ISI lifted their target price on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wells Fargo & Company lifted their price objective on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Jefferies Financial Group set a $160.00 target price on Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. HSBC assumed coverage on Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Repligen in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $177.92.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $166.82 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The stock has a market capitalization of $9.39 billion, a P/E ratio of 8,345.17, a P/E/G ratio of 3.03 and a beta of 1.12. The business has a 50-day moving average of $160.87 and a two-hundred day moving average of $140.34. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $188.81 million for the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The firm’s revenue was up 21.9% compared to the same quarter last year. During the same period last year, the business earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.